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Abstract 
Recurrent aphthous stomatitis (RAS) is the most common chronic disease of the oral cavity, affecting 5-25% of the 
population. The underlying etiology remains unclear, and no curative treatment is available.
The present review examines the existing treatments for RAS with the purpose of answering a number of questions: 
How should these patients be treated in the dental clinic? What topical drugs are available and when should they be 
used? What systemic drugs are available and when should they be used?
A literature search was made of the PubMed, Cochrane and Scopus databases, limited to articles published between 
2008-2012, with scientific levels of evidence 1 and 2 (metaanalyses, systematic reviews, phase I and II randomized 
clinical trials, cohort studies and case-control studies), and conducted in humans.
The results obtained indicate that the management of RAS should be based on identification and control of the 
possible predisposing factors, with the exclusion of possible underlying systemic causes, and the use of a detailed 
clinical history along with complementary procedures such as laboratory tests, where required. 
Only in the case of continuous outbreaks and symptoms should drug treatment be prescribed, with the initial appli-
cation of local treatments in all cases. A broad range of topical medications are available, including antiseptics 
(chlorhexidine), antiinflammatory drugs (amlexanox), antibiotics (tetracyclines) and corticosteroids (triamcinolone 
acetonide). 
In patients with constant and aggressive outbreaks (major aphthae), pain is intense and topical treatment is unable to 
afford symptoms relief. Systemic therapy is indicated in such situations, in the form of corticosteroids (prednisone) 
or thalidomide, among other drugs.
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Introduction
Recurrent aphthous stomatitis (RAS) is characterized 
by the appearance of initially necrotic ulcers, with well 
defined limits surrounded by an erythematous halo. The 
lesions are located on the oral mucosa, but are infrequent 
on the gums (1,2). The disease manifests in the form of 
outbreaks, with a chronic and self-limiting course in most 
cases (3,4). RAS is the most frequent chronic disease of 
the oral cavity, affecting 5-25% of the population (3-6). 
It is more common in patients between 10-40 years of 
age, and predominantly affects women and individuals 
of higher socioeconomic levels (1,3,7).
The underlying etiology is not clear, though a series of 
factors are known to predispose to the appearance of 
oral aphthae, including genetic factors, food allergens, 
local trauma, endocrine alterations (menstrual cycle), 
stress and anxiety, smoking cessation, certain chemical 
products and microbial agents (2-5,8,9). Immune altera-
tions have been observed, beginning with an unknown 
antigenic stimulation of the keratinocytes, and resulting 
in the activation of T lymphocytes, cytokine secretion 
(including tumor necrosis factor-alpha (TNF-α)), and 
leukocyte chemotaxis. TNF-α is believed to play an im-
portant role in the development of new RAS lesions, and 
has been found to be increased 2- to 5-fold in the saliva 
of affected patients (10). Changes have also been repor-
ted in elements of the salivary defense system, such as 
the enzyme superoxide dismutase (SOD), which parti-
cipates in the inflammatory response of RAS (11). An 
increase is moreover observed in the expression of vas-
cular and keratinocyte adhesion molecules. This gives 
rise to the accumulation of lymphocytes and lymphocyte 
infiltration of the epithelium, with the induction of ulcer 
formation (3,4,12). On the other hand, many systemic 
diseases are known to be associated with oral aphthae, 
including Behçet’s syndrome, hematological disorders, 
vitamin deficiencies, gastrointestinal diseases, cyclic 
neutropenia, Reiter syndrome, Magic syndrome, PFA-
PA (periodic fever, aphthous pharyngitis and cervical 
adenopathy), Sweet syndrome and immune deficiencies 
(1,13).
As regards the clinical manifestations, the basic lesion 
is a recurrent, painful, rounded or oval ulcer with a ne-
crotic base. Three clinical subtypes of RAS have been 
established according to the magnitude, number and du-
ration of the outbreaks (12):
• Minor RAS: This is the most common presentation 
of the disease, representing 70-85% of all cases. It 
manifests as small rounded or oval lesions covered 
by a grayish-white pseudomembrane and surrounded 
by an erythematous halo. Each minor RAS episode 
usually involves the appearance of 1-5 ulcers mea-
suring under 1 cm in diameter. These episodes are 
self-limiting and resolve within 4-14 days without 
leaving scars (3-5,7,9).
• Major RAS: This is the most severe presentation of 
the disease, representing 10% of all cases. In this 
subtype the ulcers measure over 1 cm in size and 
tend to appear on the lips, soft palate and pharynx. 
The lesions persist for over 6 weeks and can leave 
scars.
• Herpetiform RAS: This subtype accounts for 1-10% 
of all cases and is characterized by recurrent out-
breaks of small, deep and painful ulcers. Up to 100 
aphthae can develop simultaneously, measuring 2-3 
mm in size, though they tend to merge to form larger 
ulcerations with an irregular contour. This presenta-
tion is more often seen in women and in patients of 
older age, in contrast to the other two clinical subty-
pes of the disease (3,4,9,12).
The diagnosis of RAS is based on the patient anam-
nesis and clinical manifestations. There is no specific 
diagnostic test, though it is essential to discard possible 
underlying systemic causes – particularly in the case of 
adults who suffer sudden outbreaks of RAS. It is advi-
sable to request a complete series of laboratory tests, in-
cluding a complete blood count, and evaluations of iron, 
vitamin B12 and folic acid. A biopsy of the lesions is 
only recommended in the case of diagnostic uncertainty, 
since the findings only indicate a simple nonspecific in-
flammatory lesion (3,4,12).
Since the cause of the disease is not known, many drugs 
have been evaluated in an attempt to palliate the symp-
toms. Treatment used is multifocal and varies according 
to the predisposing factors. In all cases management is 
symptomatic, and seeks to reduce inflammation of the 
aphthae and afford pain relief by administering topical 
or systemic treatments (1,2).
The present literature review examines the existing 
treatments for RAS with the purpose of answering a 
number of questions: How should these patients be trea-
ted in the dental clinic? What topical drugs are available 
and when should they be used? What systemic drugs are 
available and when should they be used?.
Material and Methods 
A literature search of the PubMed, Cochrane and Sco-
pus databases was made using the key words recurrent 
aphthous stomatitis, treatment and clinical management, 
combined and related by means of the boolean operator 
AND. The search was limited to articles published bet-
ween 2008-2012, with scientific levels of evidence 1 and 
2 (metaanalyses, systematic reviews, phase I and II ran-
domized clinical trials, cohort studies and case-control 
studies), and conducted in humans. A total of 33 articles 
were identified: one metaanalysis, one cohort study, 3 
systematic reviews and 24 phase I and II randomized 
clinical trials. We also included four literature reviews, 
due to their interest and recent publication.
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Results and Discussion
The literature describes different approaches to the ma-
nagement of RAS. As a first consideration, we will des-
cribe the recommendations on how these patients should 
be treated in the dental clinic.
- Initial clinical evaluation and non-pharmacological 
treatment
A first requirement is a full and detailed clinical history 
(3,4). Some authors recommend complementary measu-
res such as a complete blood test including red cell count, 
folic acid, ferritin and vitamin B12, with the purpose of 
discarding possible underlying systemic causes (vitamin 
deficiencies, gastrointestinal disease, Behçet’s syndro-
me, immune deficiencies) – particularly in the case of 
adults who suffer sudden outbreaks of RAS, in patients 
with major aphthae, or when there are also lesions in 
other parts of the body (3,4,9). Due to the relationship 
between RAS and vitamin deficiencies, some authors 
such as Volkov et al. (8) have reported that treatment 
with vitamin B12, apart from being simple, inexpensive 
and of low risk, proves effective in application to RAS, 
even independently of the serum vitamin B12 levels of 
the patient. Other investigators such as Baccaglini et 
al. have reported similar results (1). Treatment with 2 
g of vitamin C a day during three months has also been 
shown to be effective, as in the study published by Yasui 
et al. (14), who documented a decrease of at least 50% 
in the frequency of RAS outbreaks with such therapy. 
However, other authors consider that daily multivitamin 
supplements are unable to reduce either the number or 
the duration of RAS outbreaks, and therefore consider 
that physicians should not recommend such supplements 
on a routine basis as preventive treatment (13).
The treatment prescribed should be conditioned to the 
severity of the disease (pain), the medical history of the 
patient, the frequency of the outbreaks, and patient tole-
rance of the medication (1,3).
In order to facilitate definition of the best treatment op-
tion, the patients can be classified according to their cli-
nical characteristics as follows:
• Type A: Brief episodes occurring only a few times 
during the year, and characterized by tolerable pain 
levels. Predisposing factors should be identified and 
controlled (e.g., avoiding local trauma, using a soft 
toothbrush, providing brushing instructions). It is ad-
visable to question the patient about his or her eating 
habits, in order to evaluate possible associations bet-
ween the disease outbreaks and certain foods. In this 
context, it is generally advisable to avoid hard foods 
(e.g., hard toasted bread), all types of nuts (walnuts, 
hazelnuts, etc.), chocolate, acid beverages or foods 
(fruit or citrus juices, tomato), salty foods, very spi-
cy food (pepper, curry) and alcoholic and carbonated 
beverages.
• Type B: Episodes develop on a monthly basis, lasting 
3-10 days, and the pain causes the patient to modify 
habits of hygiene and diet. If a predisposing factor 
is identified (trauma, stress, diet, hygiene, etc.), it 
should be commented with the patient and contro-
lled. It is important to question about prodromic ma-
nifestations (itching or swelling), in order to provide 
topical treatment when these occur.
• Type C: The episodes are very painful, with chronic 
aphthae. Some lesions develop while others heal, and 
the patient does not respond to topical treatment. In 
such cases systemic therapy is indicated (1,3,4,12).
- Local pharmacological treatment
Treatment should always start with topical medication 
(Table 1). The first line treatment options comprise an-
tiseptics and antiinflammatory drugs/analgesics such as 
0.2% chlorhexidine in rinses or gel, three times a day 
(without swallowing), for as long as the lesions persist. 
Triclosan can also be used in gel or rinse format three 
times a day (without swallowing), for as long as the le-
sions persist, and affords antiinflammatory, antiseptic 
and analgesic effects. In turn, topical 3% diclofenac with 
2.5% hyaluronic acid can be applied to lessen the pain 
(12). There have also been reports of the use of oral rin-
ses with benzidamine hydrochloride, which offers tem-
porary pain relief (1,12).
Amlexanox is a widely studied drug that offers short-
term efficacy, particularly when used in the prodromic 
(early symptoms) phase. Its mechanism of action is not 
known, though it is a topical agent with established anti-
inflammatory and antiallergic properties (1). It is usually 
supplied in the form of an ointment at a concentration 
of 5%, and is applied 2-4 times a day. The drug has 
been shown to be effective in accelerating the healing 
Table 1. Local pharmacological treatments.
LOCAL PHARMACOLOGICAL TREATMENTS
1.Antiseptics, anti-inflammatory and analgesics (chlorhexidine mouthwash or gel 3 0.2% v / d; triclosan gel 3 v / d; topical diclofenac 
3%; ointment amlexanox 5% 2-4 v / d).
2.Antibiotics (doxycycline gel at low doses).
3.Topical corticosteroids (triamcinolone acetonide 0.05-0.5% 3-10 v / d, fluocinolone acetonide 0.025 to 0.05% 5.10 v / d; Clobetasol 
Propionate 0.025%).
4.Hyaluronic acid (0.2% gel 2 v / d two weeks).
5.Topical anesthetics (topical lidocaine 2% spray or gel).
6.Other: Laser, natural substances ... (Nd: YAG, myrtle, quercetin, rosa damascena).
(v/d= times a day)
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of aphthae and in lessening the pain, erythema and size 
of the lesions (7). It has also been studied in other pre-
sentations such as oral patches, tablets or adhesive films. 
Meng et al. (7) observed no significant differences in 
efficacy between the application of amlexanox in patch 
or tablet form, though patients appear to prefer the for-
mer presentation.
Topical antibiotics such as tetracyclines and their deri-
vatives (doxycycline and minocycline), in gel or rinse 
format, have also been found to lessen the pain and out-
breaks of RAS. These drugs act through the local inhibi-
tion of collagenases and metalloproteinases (MPs) that 
form part of the inflammatory response and contribute 
to tissue destruction and ulcer formation, and moreover 
exert immune modulating effects (1). Of the commer-
cially available tetracyclines, doxycycline has shown 
the best inhibition of MPs (15). The administration of 
fixed-dose doxycycline in mucoadhesive gel format has 
been shown to be effective in treating RAS. Other au-
thors recommend its application at a dose of 100 mg in 
10 ml of water, performing rinses for 2-3 minutes (wi-
thout swallowing), four times a day during three days 
(12). The topical use of tetracyclines and retinoic acid 
also exerts an antiinflammatory effect, in addition to the 
known antibiotic action (16).
The most widely used drugs in immune-mediated oral 
mucosal diseases are the topical corticosteroids. The 
aim of such treatment is to eliminate the symptoms, 
thereby allowing the patient to eat, speak and perform 
normal oral hygiene, since topical corticosteroids reduce 
or even suppress the pain and shorten the aphthae hea-
ling time (6). In patients with RAS, the indicated drugs 
are triamcinolone acetonide, fluocinolone acetonide or 
clobetasol propionate, in order of lesser to greater poten-
cy, according to the severity of the lesions. These three 
drugs can be administered as a pomade in orabase when 
the lesions are of a localized nature, or in rinse format 
when the lesions are diffuse or very numerous. Triamci-
nolone acetonide is used at concentrations ranging from 
0.05-0.5%, applied 3-10 times a day during 3-5 minu-
tes. It is particularly indicated in patients with small and 
mild erosive lesions. Some authors consider the most 
effective concentration to be 0.1% (6,12,16). In order to 
facilitate healing, it is advisable to apply the medication 
directly onto the lesions, keeping it in direct contact for 
as long as possible, and taking care not to eat or drink 
during 20 minutes after application, or touch the trea-
ted zone. If the corticosteroid is administered as an oral 
rinse, it should be used for the indicated period of time, 
without swallowing the product. On the other hand, fluo-
cinolone acetonide at a concentration of 0.025-0.05%, 
applied 5-10 times a day during 3-5 minutes, affords 
medium to high potency, and is widely used in patients 
with more aggressive lesions. Lastly, 0.025% clobetasol 
propionate is the most potent topical corticosteroid, and 
is therefore reserved for moderate or severe disease pre-
sentations. In this context, it is regarded as an alternative 
prior to the prescription of systemic therapy (6,12).
Another evaluated topical corticosteroid is dexametha-
sone. Liu et al. (17) investigated the efficacy and safety 
of dexamethasone pomade in treating RAS. They eva-
luated the size of the aphthae and their duration, as well 
as the intensity of pain, and concluded that the pomade 
is effective and safe when used in such situations. Al-
Na´mah et al. (18) in turn compared a dexamethasone 
pomade with the commonly used triamcinolone acetoni-
de formulation in orabase, and found both products to be 
equally effective in treating RAS.
Other topical treatments that have been used in RAS are 
0.2% hyaluronic acid in gel formulation, applied twice 
a day during two weeks (19); topical anesthetics such 
as 2% lidocaine (as a spray or gel); adhesive toothpas-
te containing polydocanol; or benzocaine tablets (3,12). 
In turn, the Nd:YAG laser has been found to afford im-
mediate pain relief and faster healing, and is well tole-
rated by patients with RAS, since it is a brief form of 
treatment, results in lesser pain after application, and has 
few side effects (20). Other treatments include natural 
substances such as myrtle (Myrtus communis), a bush 
from northern Iran that possesses blood glucose-lowe-
ring, antibacterial, analgesic and antioxidant properties, 
thus suggesting potential usefulness in application to di-
seases characterized by inflammation and allergy (21); 
quercetin, a flavonol found in fruits and vegetables, with 
antioxidant properties and which may prove useful in 
shortening aphthae healing time when applied as daily 
topical treatment (22); bioadhesive patches containing 
licorice hydrogel, which reduce the diameter of the in-
flammatory halo and the necrotic center of the aphthae, 
and the pain they produce (23); or oral rinses containing 
an aqueous extract of Damask rose, which possesses an-
tiinflammatory and antinociceptive properties (24).
- Systemic pharmacological treatment
The outbreaks of RAS are normally resolved with topical 
treatments, though in some cases these measures prove 
insufficient because of the severity of the lesions or for 
unknown reasons. This is when second line therapy with 
systemic drug substances is indicated (Table 2).
Studies have been made of systemic antibiotics such as 
potassium penicillin G in 50 mg tablets administered 
four times a day during four days, which help reduce 
the size of the ulcers and lessen the pain (5). The oral 
antipoliomyelitic vaccine has also been found to signifi-
cantly reduce the duration of the aphthae, the frequency 
of outbreaks, and their severity (25).
The most effective treatments include corticosteroids and 
immunosuppressors. Pentoxifylline, colchicine, dapsone 
and thalidomide have also been used, but require caution 
because of possible adverse effects. These treatments are 
essentially palliative, since none of them have been able 
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to secure permanent disease remission (26).
Corticosteroids are the first choice systemic treatment. 
They are usually used as rescue therapy in patients with 
acute severe RAS outbreaks (27). Oral prednisone has 
been used at a starting dose of 25 mg/day, followed by 
stepwise dose reduction, during two months, with di-
sappearance of the pain and reepithelization of the le-
sions in the first month of therapy (26). The drug can 
produce long-term adverse effects; as a result, its effica-
cy has been compared with that of other drugs, in search 
of an alternative treatment. In this context, Femiano et 
al. (2) compared the efficacy of prednisone prescribed at 
a dose of 25 mg/day via the oral route during 15 days, 
12.5 mg/day during 15 days, 6.25 mg/day during 15 
days, and then 6.25 mg on alternate days during 15 days, 
in comparison with montelukast (a leukotriene receptor 
antagonist used as an antiasthma drug) 10 mg via the 
oral route each night, followed by administration on al-
ternate days during the second month. The authors found 
both treatment modalities to be effective in reducing the 
number of lesions, affording pain relief and accelerating 
healing of the ulcers. As regards adverse effects, mon-
telukast was found to be safer, and therefore should be 
taken into account as an option when systemic corticos-
teroids are contraindicated. In another comparative stu-
dy, Pakfetrat et al. (28) compared prednisolone 5 mg/day 
versus colchicine (a drug that interferes with different 
pathways of the inflammatory process) 0.5 mg/day. Both 
treatments were seen to be equally effective and signi-
ficantly reduced the lesion outbreaks, though colchicine 
produced more side effects. Thus, 5 mg/day of predniso-
lone seems to be a better option in reducing the signs and 
symptoms of the disease.
Zinc is an essential cofactor with effects upon wound 
reepithelization and healing that has also been investi-
gated as a possible treatment for RAS at a dose of 150 
mg, compared with dapsone (an antiinfectious sulfone 
used to treat leprosy and other skin conditions) at a dose 
of 50 mg. Both treatments were found to have important 
therapeutic and prophylactic properties in application to 
RAS, though zinc sulfate produced much faster and sus-
tained effects (29).
Clofazimine is an antimicrobial used for the treatment of 
leprosy is combination with other drugs such as rifampi-
cin and dapsone. In application to severe RAS, and when 
administered at a dose of 100 mg/day during 6 months, 
the drug was found to avoid the appearance of new le-
sions during the mentioned treatment period (27).
Scully et al. (12) recommend the use of pentoxifylline, 
and inhibitor of tumor necrosis factor-alpha (TNF-α), 
and of neutrophil function and chemotaxis, at a dose 
of 400 mg three times a day during one month to ob-
tain beneficial effects in patients with RAS. However, 
the authors underscore that the drug does not avoid the 
appearance of new outbreaks and has numerous adver-
se effects (particularly of a gastrointestinal nature). As a 
result, they consider that pentoxifylline should be used 
as a second line treatment option in patients that fail to 
respond to other therapies, or as a coadjuvant to other 
treatments.
Immune modulators may be useful as second line 
treatment in different oral diseases such as oral lichen 
planus, and particularly in recurrent aphthous stomatitis 
(16). In this context, thalidomide, an immune modula-
tor widely used in RAS, is recommended at a dose of 
50-100 mg/day (12). Hello et al. (30) conducted a re-
trospective cohort study of 92 patients with severe RAS 
who had received treatment in the form of thalidomide. 
The authors found that 85% of the patients (78/92) ex-
perienced complete remission of the lesions in the first 
14 days. However, 84% of the subjects suffered adverse 
effects. Thalidomide is known to produce many adverse 
effects, including teratogenicity, polyneuropathy, drow-
siness, constipation, increased appetite, headache, nau-
sea and gastric pain (12,30). Another immune modulator 
is levamisole, which restores normal phagocytic activity 
among macrophages and neutrophils, and modulates T 
cell mediated immunity. The drug shortens the duration 
of the aphthae outbreaks, as well as the number, size 
and frequency of the lesions (12,31). At a dose of 150 
mg three times a week during 6 months, the drug is safe 
(31), though adverse effects have also been described, 
SYSTEMIC PHARMACOLOGICAL TREATMENTS
1.Antibiotics (penicillin G potassium, 50 mg pills 4 v / d 4 days).
2.Corticosteroids (initial dose of oral prednisone 25 mg / day and stepwise dose reduction for 2 months).
3.Colchicine (0.5 mg / day 7 days, 1 mg / day 7 days and a maintenance dose of 1.5 mg / day).
4.Dapsone (25 mg / day 3 days, 50 mg / day 3 days, 75 mg / day 3 days and a maintenance dose of 100 mg / day).
5.Clofazimine (100 mg daily for 6 months).
6.Pentoxifylline (400 mg 3 v / d for one month).
7.Zinc sulphate (150 mg / d).
8.Immunomodulating: thalidomide (50-100 mg per day), levamisole (150 mg three times a week during 6 months).
9.Homeopathic substances (mercurius solubilis, Natrum muriaticum, phosphorus, sulfuric acid, nitric acid ... 100 ml of water orally 
every 12 hours for 6 days).
(v/d= times a day)
Table 2. Systemic pharmacological treatments.
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including nausea, hyperosmia, dysgeusia and agranulo-
cytosis (12,31). 
Mimura et al. (32) compared the efficacy of four syste-
mic treatments for severe RAS. Prednisone was admi-
nistered during two weeks, starting with 0.5 mg/kg/day 
as a single morning dose, and followed after one week 
by a reduction to half the starting dose. At the same time, 
the patients were randomly assigned to one of the fo-
llowing drugs during 6 months: thalidomide (100 mg/
day), dapsone (25 mg/day during 3 days, 50 mg/day du-
ring 3 days, 75 mg/day during 3 days, and a maintenance 
dose of 100 mg/day), colchicine (0.5 mg/day during 7 
days, 1 mg/day during 7 days, and a maintenance dose 
of 1.5 mg/day) or pentoxifylline (400 mg 3 times a day). 
Thalidomide was found to be the most effective and best 
tolerated treatment, with complete resolution of the RAS 
outbreak in 87.5% of the patients. Pentoxifylline produ-
ced benefits in 60% of the cases.
Lastly, other systemic treatments have been described, 
including homeopathic medicines containing borax, 
mercurius solubilis, natrum muriaticum, phosphorus, 
sulfuric acid, nitric acid, arsenicum album, nux vomica 
and lycopodium. These substances, diluted in 100 ml of 
water and administered via the oral route every 12 hours 
during 6 days reduced the intensity of pain and the size 
of the ulcers. None of the subjects had to suspend the 
treatment because of adverse effects. However, there 
is still not enough evidence to either support or refute 
the use of homeopathic medicines as treatment for RAS 
(33).
Conclusions
- How should these patients be treated in the dental cli-
nic?
Possible underlying systemic causes must be discarded, 
based on a detailed clinical history, together with com-
plementary procedures such as laboratory tests, where 
required.
The predisposing factors must be identified and contro-
lled. 
The severity of the outbreak must be evaluated, along 
with the type of aphthae and the frequency of outbreaks. 
Only when the outbreaks and symptoms are continuous 
should drug treatment be used, and starting in all cases 
with local drug treatment.
- What topical drugs are available and when should they 
be used?
Whenever drug treatment proves necessary, because the 
outbreaks are continuous and the pain affects patient 
quality of life, the first option is topical treatment. If the 
patient recognizes the prodromic manifestations (early 
symptoms) of the disease, antiinflammatory agents such 
as 5% amlexanox, or topical corticosteroids such as 
0.1% triamcinolone acetonide, are particularly indica-
ted in order to prevent the formation of lesions. In the 
case of already established aphthae, the abovementioned 
drugs can be used to lessen the inflammation, though in 
combination with antiseptics such as chlorhexidine and 
triclosan, antibiotics such as tetracyclines, hyaluronic 
acid or pomades containing natural substances such as 
myrtle or quercetin, among others, with a view to affor-
ding pain relief and to accelerate ulcer healing.
- What systemic drugs are available and when should 
they be used?
Systemic drug treatment is indicated when the outbreaks 
are constant and aggressive, with major aphthae, the 
pain is intense, and topical treatment is unable to afford 
symptoms relief. Different drugs can be used to control 
the symptoms, such as colchicine 1.5 mg/day, dapsone 
50 mg/day, clofazimine 100 mg/day or pentoxifylline 
400 mg 3 times a day - though the most widely used 
treatment consists of systemic corticosteroids such as 
prednisone 25 mg/day and immune modulators such as 
thalidomide 50-100 mg/day, affording complete or al-
most complete remission of the outbreaks – though the 
possibility of side effects must be taken into account.
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